Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

3Sync LLC

Neither a doctor nor a teaching hospital

Research payments

$14,215,645

361 payments

Through program year 2025, 3Sync LLC is reported as receiving $14,215,645 in research payments, across 361 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,668,878 157
2024 Research $5,273,944 105
2023 Research $7,272,823 99

Breakdown

Who paid Research payments · program years 2023–2025
  1. Genentech, Inc. $12,843,286 280 payments
  2. Gen-Probe, Inc. $967,411 33 payments
  3. Ionis Pharmaceuticals, Inc. $249,051 19 payments
  4. Teva Pharmaceuticals USA, Inc. $45,705 18 payments
  5. Shionogi Inc $44,013 7 payments
  6. E.R. Squibb & Sons, L.L.C. $34,328 2 payments
  7. Sanofi US Services Inc. $22,400 1 payment
  8. Chiesi USA, Inc. $9,450 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. Roche Cancer Screening Collection Study $12,843,286 280 payments
  2. A10940-SC2/FluP-CSP-02 $926,559 32 payments
  3. Is354cs9 $249,051 19 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma $45,022 13 payments
  5. A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults $44,013 7 payments
  6. A10960-Sc2p-Csp-01 / A10960-Sc2p-Csp-02 $40,852 1 payment
  7. A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis $34,328 2 payments
  8. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $22,400 1 payment
  9. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $9,450 1 payment
  10. A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma $684 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record